JB
Adocia Pipeline
| Drug | Indication | Phase |
|---|---|---|
| BioChaperone® Lispro (THDB0206) | Type 1 Diabetes | Phase 3 |
| BioChaperone® Lispro | Type 2 Diabetes | Phase 3 |
| BioChaperone® Combo (Insulin Glargine / Lixisenatide) | Type 2 Diabetes | Phase 2 |
| BioChaperone® Glucagon | Hypoglycemia | Phase 1 |
| AdOral® Insulin | Diabetes | Preclinical |
| AdoShell® Islet Cell Therapy | Type 1 Diabetes | Preclinical |
| AdoXLong Platform | Diabetes & Obesity | Discovery |
Leadership Team at Adocia
OS
Olivier Soula
Chief Executive Officer, Co-founder
MG
Mathieu-William Gilbert
Chief Financial Officer - Chief Operating Officer
MG
Martin Gaudier
Research & Development Director
YP
You Ping Chan
Research & Development Director
ED
Emmanuel Dauty
Innovation & Physico Chemistry Department Director
DR
David Rigal
Pharmaceutical Operations Director
GF
Géraldine Favre Soula
Director of human resources
SB
Stéphane Boissel
Chairman of the Board
VM
Valérie Moumdjian
Board member
MD
Mads Dall
Board member